BioTime closes acquisition of Asterias Biotherapeutics

|By:, SA News Editor

BioTime (NYSEMKT:BTX) closes its previously reported acquisition of Asterias Biotherapeutics, acquiring all of the remaining outstanding common stock of Asterias.

Following the closing of the merger, BioTime owns approx. 84% of the combined company, and prior Asterias stockholders own approx. 16%.

BioTime is now advancing three clinical stage product candidates for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer.

Subscribe for full text news in your inbox